Health Net Federal Services Earns Distinction with Renewed URAC Accreditations

Our Bureau

Health Net Federal Services, LLC (HNFS), a Centene Corporation (NYSE: CNC) subsidiary, announced its renewed Utilization Review Accreditation Commission (URAC) accreditations in Health Network, Health Utilization Management, Case Management, and Disease Management. This achievement underscores HNFS’s ongoing commitment to quality care, enhanced processes, patient safety, and improved outcomes for the U.S. military service members, retirees, and family members it serves.

URAC is an independent accreditation organization committed to promoting healthcare quality by setting high standards for clinical practice, consumer protections, performance measurement, operations infrastructure, and risk management.

Kathleen Redd, President, and CEO of Health Net Federal Services, said, “Upholding these accreditations reflects our dedication to delivering exceptional healthcare solutions. We are proud of our longstanding commitment to excellence, and we remain focused on advancing our capabilities to provide the best possible support and outcomes for those who serve our nation.”

Organizations awarded URAC’s in Health Network, Utilization, Disease, and Case Management accreditation demonstrate excellence in network management, high-quality performance, chronic disease management, patient engagement, and care coordination. HNFS has held URAC’s Health Network, Health Utilization, and Case Management accreditations since 2005 and URAC’s Disease Management accreditation since 2011, demonstrating a continuous commitment to excellence.

“Health care professionals know that health network management, utilization management, case management, and disease management are important components to ensuring that patients receive the most appropriate care for their needs. Achieving URAC accreditation and earning our gold star demonstrates excellence in maximizing patient experience and plan performance across the care continuum. We are proud to recognize Health Net Federal Services for their commitment to excellence,” said URAC’s President and CEO Shawn Griffin, MD.


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology

MediLink Therapeutics (“MediLink”), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors. Under the terms of the agreement, MediLink will grant Roche exclusive […]
YL211 Antibody-Drug Conjugate Development Collaboration

Subscribe Now